Vaxfectin™ enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines

This publication has 24 references indexed in Scilit:

• A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores
  Proceedings of the National Academy of Sciences, 2004
• Phase 1 Evaluation of 3 Highly Immunogenic Prime‐Boost Regimens, Including a 12‐Month Reboosting Vaccination, for Malaria Vaccination in Gambian Men
  The Journal of Infectious Diseases, 2004
• Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection
  Vaccine, 2004
• A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans
  Journal of General Virology, 2004
• Enhancing Effect of Vaxfectin on the Ability of a Japanese Encephalitis DNA Vaccine to Induce Neutralizing Antibody in Mice
  Viral Immunology, 2003
• Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
  Nature Medicine, 2003
• Improved Tuberculosis DNA Vaccines by Formulation in Cationic Lipids
  Infection and Immunity, 2002
• Dna Prime/Canarypox Boost—Based Immunotherapy of Chronic Hepatitis B Virus Infection in A Chimpanzee
  Hepatology, 2001
• Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine
  Science, 1998
• Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein.
  Proceedings of the National Academy of Sciences, 1994